Clearmind Medicine Inc. (NASDAQ:CMND) ("Clearmind" or the "Company"), a clinical-stage biotech company focused on the discovery and development of novel, non-hallucinogenic, second generation, neuroplastogen-derived therapeutics to solve major under-treated health problems, today announced the successful completion of treatment for all participants in Part A of its ongoing Phase I/II clinical trial evaluating CMND-100 for the treatment of Alcohol Use Disorder (AUD).

All 24 participants across Cohorts 1 through 4 have successfully completed treatment according to the study protocol.

The Company is currently assessing the dataset and, assuming results remain favorable, intends to initiate the next stage of the clinical program in Alcohol Use Disorder patients.